Sydney, Australia – November 21, 2025 – DeRoyal Industries, Inc a global leader in healthcare innovation and Heal‑Med Solutions Pty Ltd, today announced the approval of key advanced wound care products by the Therapeutic Goods Administration (TGA) for use in Australia. This milestone marks the beginning of a strategic relationship aimed at expanding access to innovative wound management solutions across the country.

 

​The newly approved products include Multidex™and Sofsorb™, both designed to support improved healing outcomes in complex wound care. With their inclusion on the Australian Register of Therapeutic Goods (ARTG), clinicians and patients will now benefit from proven technologies that enhance treatment options and patient care.

 

​“We are delighted to partner with Heal‑Med Solutions to bring DeRoyal’s advanced wound care portfolio to Australia,” said Devon Reid - Director of Sales (Canada & South Pacific)for DeRoyal Industries. “Together, we are committed to delivering innovation that makes a real difference in patient outcomes.”

 

​“The approval of Multidex™ and Sofsorb™ represents an important step forward for Heal‑Med Solutions,” said Milner Fernandes, Commercial Director of Heal‑Med Solutions. “We look forward to working closely with healthcare providers and procurement teams to ensure these products are available where they are needed most.”

 

This collaboration combines DeRoyal’s global expertise with Heal‑Med’s local distribution, ensuring Australian healthcare providers gain access to world‑class wound care solutions.